Cereno Scientific – executive interview

In this interview, we speak with Sten Sörensen, CEO of Cereno Scientific, about the key takeaways from the company’s FY25 results and recent progress across its cardiopulmonary pipeline. Sten outlines the rationale behind Cereno’s HDAC inhibition platform and its lead programmes CS1 and CS014, which target underlying disease mechanisms in pulmonary hypertension and related conditions. The discussion focuses on CS1’s upcoming Phase IIb trial in pulmonary arterial hypertension (PAH), insights expected from the expanded access programme and recent developments in the competitive landscape, including GSK’s $950m acquisition of 35Pharma (centred on its lead asset HS235) and the recent Phase III failure of seralutinib. Sten also explains the decision to expand CS014 into pulmonary hypertension associated with interstitial lung disease (PH-ILD) and provides an update on ongoing partnering discussions. He concludes by highlighting key milestones expected over the next 12–18 months, including clinical readouts and trial initiations.

Cereno Scientific (STO: CRNO-B) is a clinical-stage biotech focused on developing innovative treatments for rare diseases in the cardiovascular and pulmonary fields. Its pipeline is led by CS1 and CS014, HDAC inhibitors with disease-modifying potential in PAH and PH-ILD, respectively. Both candidates are supported by encouraging clinical data and are advancing towards later-stage clinical trials (Phase IIb for CS1 in Q226 and Phase II for CS014 in Q127). A third asset, CS585, a prostacyclin receptor agonist, is currently under preclinical evaluation for cardiovascular indications.